INTESTINAL AND PLACENTAL FC-RECEPTORS FOR IMMUNOGLOBULIN
Project Number5R01HD027691-09
Contact PI/Project LeaderSIMISTER, NEIL E
Awardee OrganizationBRANDEIS UNIVERSITY
Description
Abstract Text
DESCRIPTION (Adapted from the applicant's abstract): Acquisition of
maternal antibodies is critical to the immunologic defense of the
newborn. In suckling rats and mice, a receptor for the Fc region of
immunoglobulin G (IgG) transports IgG from milk across the intestinal
epithelium into the blood. This receptor, FcRn, for neonate, is similar
in structure to class I major histocompatibility complex proteins. Late
in gestation the same receptor appears to transport IgG across the fetal
yolk sac in these species. Prenatal transport accounts for only a small
fraction of the maternal IgG that rodents receive, but in humans IgG
transport occurs mostly, and perhaps only, before birth. A homolog of
FcRn is expressed in human placenta and is likely to mediate materno-
fetal IgG transport.
A major goal of this proposal is to determine whether human FcRn is
indeed responsible for placental IgG transport. Specific aims toward
this goal include the localization of FcRn in human placenta by
immunocytochemistry and in situ hybridization. The presence of the
receptor in one or both of the cellular barriers between maternal and
fetal blood, the syncytiotrophoblast and fetal vessel endothelia, would
be consistent with a transport role. The specificity of human FcRn for
different human IgG subclasses, measured by a competitive binding assay,
will be compared with the relative efficiency of placental transport of
these subclasses. A relatively low affinity for IgG2, which is
transported poorly, would suggest that FcRn has a role in IgG transport
from mother to fetus.
The molecular mechanism of transcytosis of IgG by FcRn is not known. The
second major goal of this proposal is to determine how this process
occurs. Specific aims related to this goal include the characterization
of the trafficking of rat FcRn functionally expressed in the polarized
Madin-Darby canine kidney cell line. Sorting signals in the cytoplasmic
region of rat FcRn will be located by site-directed mutagenesis and
expression of mutant receptors in MDCK cells. Proteins that interact
with sorting signals will be sought using a yeast two-hybrid method.
The clinical importance of maternal IgG for the immunologic defense of
the neonate is well established. Because most IgG is transmitted to the
fetus late in pregnancy, very premature infants have low serum IgG and
are especially vulnerable to infection. Not all antibodies are
beneficial, however: the health of the newborn may be compromised by
the acquisition of anti-rhesus and anti-ABO antibodies. Transmission
of autoantibodies in systemic lupus erythematosus, myasthenia gravis,
and other autoimmune diseases of the mother may also be damaging to the
fetus. This proposal aims to contribute to our understanding of the
mechanism of antibody transport from mother to young, and thus to
increase the basis for rational intervention in pregnancies complicated
by potentially harmful maternal immune responses.
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
865
DUNS Number
616845814
UEI
MXLZGAMFEKN5
Project Start Date
01-February-1991
Project End Date
31-March-2000
Budget Start Date
01-April-1999
Budget End Date
31-March-2000
Project Funding Information for 1999
Total Funding
$184,880
Direct Costs
$118,894
Indirect Costs
$65,986
Year
Funding IC
FY Total Cost by IC
1999
Eunice Kennedy Shriver National Institute of Child Health and Human Development
$184,880
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01HD027691-09
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01HD027691-09
Patents
No Patents information available for 5R01HD027691-09
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01HD027691-09
Clinical Studies
No Clinical Studies information available for 5R01HD027691-09
News and More
Related News Releases
No news release information available for 5R01HD027691-09
History
No Historical information available for 5R01HD027691-09
Similar Projects
No Similar Projects information available for 5R01HD027691-09